ALSUntangled # 69: astaxanthin.
Publication
, Journal Article
Fullam, T; Armon, C; Barkhaus, P; Barnes, B; Beauchamp, M; Benatar, M; Bertorini, T; Bowser, R; Bromberg, M; Mascias Cadavid, J; Carter, GT ...
Published in: Amyotroph Lateral Scler Frontotemporal Degener
August 2023
ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review astaxanthin which has plausible mechanisms for slowing ALS progression including antioxidant, anti-inflammatory, and anti-apoptotic effects. While there are no ALS-specific pre-clinical studies, one verified "ALS reversal" occurred in a person using a combination of alternative therapies which included astaxanthin. There have been no trials of astaxanthin in people living with ALS. Natural astaxanthin appears to be safe and inexpensive. Based on the above information, we support further pre-clinical and/or clinical trials of astaxanthin in disease models and PALS, respectively, to further elucidate efficacy.
Duke Scholars
Published In
Amyotroph Lateral Scler Frontotemporal Degener
DOI
EISSN
2167-9223
Publication Date
August 2023
Volume
24
Issue
5-6
Start / End Page
553 / 557
Location
England
Related Subject Headings
- Humans
- Complementary Therapies
- Amyotrophic Lateral Sclerosis
- 3209 Neurosciences
- 1109 Neurosciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Fullam, T., Armon, C., Barkhaus, P., Barnes, B., Beauchamp, M., Benatar, M., … Bedlack, R. (2023). ALSUntangled # 69: astaxanthin. Amyotroph Lateral Scler Frontotemporal Degener, 24(5–6), 553–557. https://doi.org/10.1080/21678421.2023.2171302
Fullam, Timothy, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Morgan Beauchamp, Michael Benatar, Tulio Bertorini, et al. “ALSUntangled # 69: astaxanthin.” Amyotroph Lateral Scler Frontotemporal Degener 24, no. 5–6 (August 2023): 553–57. https://doi.org/10.1080/21678421.2023.2171302.
Fullam T, Armon C, Barkhaus P, Barnes B, Beauchamp M, Benatar M, et al. ALSUntangled # 69: astaxanthin. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5–6):553–7.
Fullam, Timothy, et al. “ALSUntangled # 69: astaxanthin.” Amyotroph Lateral Scler Frontotemporal Degener, vol. 24, no. 5–6, Aug. 2023, pp. 553–57. Pubmed, doi:10.1080/21678421.2023.2171302.
Fullam T, Armon C, Barkhaus P, Barnes B, Beauchamp M, Benatar M, Bertorini T, Bowser R, Bromberg M, Mascias Cadavid J, Carter GT, Dimachkie M, Ennist D, Feldman EL, Heiman-Patterson T, Jhooty S, Lund I, Mcdermott C, Pattee G, Ratner D, Wicks P, Bedlack R. ALSUntangled # 69: astaxanthin. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5–6):553–557.
Published In
Amyotroph Lateral Scler Frontotemporal Degener
DOI
EISSN
2167-9223
Publication Date
August 2023
Volume
24
Issue
5-6
Start / End Page
553 / 557
Location
England
Related Subject Headings
- Humans
- Complementary Therapies
- Amyotrophic Lateral Sclerosis
- 3209 Neurosciences
- 1109 Neurosciences
- 1103 Clinical Sciences